Browse News
Filter News
Found 8 articles
-
Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics
12/19/2023
Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics.
-
Atavistik Bio Appoints Bryan Stuart as Chief Executive Officer
7/17/2023
Atavistik Bio today announced the appointment of Bryan Stuart as Chief Executive Officer (CEO) and a Director on the company’s Board.
-
AviadoBio Announces Appointment of Jeff Goater as Chair of the Board of Directors
2/1/2023
AviadoBio, a pioneering, pre-clinical stage gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, announced the appointment of Jeff Goater as Chair of the AviadoBio Board of Directors, effective immediately.
-
Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics
1/10/2023
Atavistik Bio announced today that it has entered into a collaboration agreement with Plex Research, a company providing a novel artificial intelligence (AI)-powered drug discovery platform.
-
Atavistik Bio Announces Formation of Scientific Advisory Board
9/20/2022
Atavistik Bio announced the formation of its Scientific Advisory Board (SAB).
-
Money on the Move: August 18 – 24
8/25/2021
The current continues as investment dollars flow into the life sciences. Here’s an overview who is catching the drift this week. -
Atavistik Bio Secures $60 Million to Leverage Metabolite-Protein Interactions Against Disease
8/24/2021
Atavistik Bio is linking a deep understanding of metabolite-protein interactions and their potential to lead to novel drugs that will restore protein function in metabolic diseases and cancers. -
Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer
8/24/2021
Atavistik Bio (“Atavistik”, “Company”), a pre-clinical biotechnology company pioneering the identification of metabolite-protein interactions that have the potential to lead to the discovery and development of first-in-class drug candidates powered by distinct allosteric control mechanisms, announced today that the Company had completed a $60 million Series A financing round.